Edwards Lifesciences (EW) Stock: Buy, Sell, or Hold?
EW - Edwards Lifesciences Corp
$88.01
-0.29 (-0.32%)
▼
5d:
+1.8%
30d:
-0.87%
90d:
+4.99%
HOLD
MODERATE Confidence
Analysis Updated: Oct 21, 2026 12:00 AM ET
Earnings: Nov 04, 2026
13d
Get Alerted When EW Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: EW shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: EW shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
EW is flagged by 1 backtest-validated scanner today
SPY Bullish (stocks from this scanner have beaten SPY by a median 0.37% over the next 20 trading days; EW has been on it 3 days). Backtested on 8 months of scanner history vs the S&P 500, as of 2026-10-21.
See all of today's Best Signals in the free scanner →Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$126.34
Based on 8.4% avg growth
INTRINSIC VALUE TODAY
$78.45
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: EW is currently trading at $88.00, which is considered extended relative to its 30-day fair value range of $85.49 to $88.09. The stock's valuation (Forward PE: 26.1) is in line with its historical norms (26.3). Remarkably, the market is currently pricing in an annual earnings decline of 0.2% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, EW is in a uptrend. The price is approaching resistance at $89.32. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: The stock scores a mixed 50/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $101.81 (+15.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, EW is in a uptrend. The price is approaching resistance at $89.32. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: The stock scores a mixed 50/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $101.81 (+15.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$85.49 -
$88.09
Company Quality Score
59/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
48.6%
Protect Your Profits
Holding EW? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BEARISH: Price extended above range
- NEUTRAL: Mixed technical signals (50/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($101.81)
- NEUTRAL: Bottoming setup forming (50/100) — watch for confirmation
Trading Range Analysis
30-Day Trading Range
$85.49 -
$88.09
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$82.43
Resistance Level
$89.32
Current Trend
Uptrend
Technical data as of
Oct 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
26.10
Wall Street Target
$101.81
(+15.3%)
Revenue Growth (YoY)
13.6%
Earnings Growth (YoY)
-25.4%
Profit Margin
15.4%
Valuation Discount vs History
-0.2% cheaper
PE vs Historical
26.1 vs 26.3
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-0.2%
(market-implied from PE analysis)
1-Year Target
$88.11
(0%)
2-Year Target
$87.94
(0%)
3-Year Target
$87.76
(-1%)
3-Yr Target (if PE normalizes)
(PE: 26→26)
$88.45
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 26.1, Growth: 12.8%)
$126.75
(+44%)
Base:
(SPY PE: 19.9, Growth: 12.8%)
$96.47
(+9%)
Bear:
(PE: 16.9, Growth: 12.8%)
$82.00
(-7%)
📈
Valuation based on Current Earnings
Forward PE: 25.64 | Forward EPS (Implied): $3.44
Bull Case
$106.61
(+21%)
Analyst growth 15.0%, PE expands to 26.9
Base Case
$88.29
(0%)
Market implied 0.0%, PE stable at 25.6
Bear Case
$67.54
(-24%)
Severe decline -15.0%, PE contracts to 23.1
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 26.1 to 26.3
Stabilization Target:
$88.98
(+0.8%)
PE Expansion Potential:
+0.8%
Share & Embed Analysis
Last updated: October 21, 2026 2:58 PM ET
Data refreshes hourly during market hours. Next update: 3:58 PM
Data refreshes hourly during market hours. Next update: 3:58 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is EW showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
DXCM
DexCom Inc |
STRONG BUY
29 analysts |
$96 | 50 HOLD |
|
BSX
Boston Scientific Corp |
STRONG BUY
31 analysts |
$59 | 50 HOLD |
|
MDT
Medtronic PLC |
BUY
29 analysts |
$105 | 43 HOLD |
|
AXGN
Axogen Inc |
STRONG BUY
12 analysts |
$54 | 75 BUY |
|
TNDM
Tandem Diabetes Care Inc |
BUY
25 analysts |
$28 | 54 HOLD |
Advanced EW Option Strategies
Professional options setups generated by AI based on today's EW price and gamma walls.
